Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Quidel Corporation (QDEL : NSDQ)

• Company Description    Quidel Corporation is in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company sells its products directly to end users and distributors for professional use. Quidel operates in business segments that develop, manufacture and market it in 4 product segments. Rapid Immunoassay - Category includes the Sofia and Sofia 2 Analyzers, QuickVue, InflammaDry and AdenoPlus. Cardiometabolic Immunoassay - Category includes the Triage MeterPro, a portable testing platform that runs a comprehensive menu of tests via the rapid diagnosis of critical diseases and health conditions, as well as detection of certain drugs of abuse. Molecular Diagnostic Solutions: This category includes the Lyra, Solana and Savanna systems. Lyra Molecular Real-Time Polymerase Chain Reaction assays provide important benefits to the customer. Specialized Diagnostic Solutions - This category includes Virology and Specialty Products. Virology product category includes the FDA-cleared bioassay, Thyretain. Number of Employees: 1,600

• Price / Volume Information    Yesterday's Closing Price: $100.60 Daily Weekly Monthly 20 Day Moving Average: 575,245 shares Shares Outstanding: 41.85 (millions) Market Capitalization: $4,209.94 (millions) Beta: 0.02 52 Week High: $180.06 52 Week Low: $88.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.32% -1.01% 12 Week 2.82% 11.13% Year To Date -25.48% -11.73%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9975 SUMMERS RIDGE ROAD - SAN DIEGO,CA 92121 USA ph: 858-552-1100 fax: 858-453-4338 rargueta@quidel.com http://www.quidel.com

• General Corporate Information    Officers Douglas C. Bryant - Chief Executive Officer and President Kenneth F. Buechler - Chairman of the Board Randall J. Steward - Chief Financial Officer Edward L. Michael - Director Kathy P. Ordonez - Director Peer Information Quidel Corporation (BJCT) Quidel Corporation (CADMQ) Quidel Corporation (APNO) Quidel Corporation (UPDC) Quidel Corporation (IMTIQ) Quidel Corporation (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 74838J101 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 41.85 Most Recent Split Date: (:1) Beta: 0.02 Market Capitalization: $4,209.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $3.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $16.30 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: 6.17 Trailing 12 Months: 4.09 PEG Ratio: - Price Ratios Price/Book: 1.74 Price/Cash Flow: 5.25 Price / Sales: 1.81 EPS Growth vs. Year Ago Period: 170.02% vs. Previous Quarter: 60.81% Sales Growth vs. Year Ago Period: 167.03% vs. Previous Quarter: 57.37% ROE 03/31/22 - 56.46 12/31/21 - 45.78 09/30/21 - 62.24 ROA 03/31/22 - 44.21 12/31/21 - 35.06 09/30/21 - 46.33 Current Ratio 03/31/22 - 4.29 12/31/21 - 4.45 09/30/21 - 3.87 Quick Ratio 03/31/22 - 3.92 12/31/21 - 3.84 09/30/21 - 3.20 Operating Margin 03/31/22 - 44.85 12/31/21 - 43.56 09/30/21 - 48.80 Net Margin 03/31/22 - 43.26 12/31/21 - 41.46 09/30/21 - 47.20 Pre-Tax Margin 03/31/22 - 55.87 12/31/21 - 53.01 09/30/21 - 60.96 Book Value 03/31/22 - 57.71 12/31/21 - 46.30 09/30/21 - 39.21 Inventory Turnover 03/31/22 - 3.10 12/31/21 - 2.17 09/30/21 - 2.20 Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©